Moffitt Cancer Center and Proteacel LLC have announced that they have entered a licensing agreement under which Proteacel has acquired the exclusive rights to the PORE™ technology for delivery of genes into cells. Genes are the instructions that build cells. Defects in these genes cause disease, such as cancer. In order to understand how these genes work and their involvement in a disease process, researchers must study and modify them. The most common way to study gene function is to transfer the gene into cells…

View post:
Accelerating The Pace Of Discovery In Cancer Research

You may also like:

• Duke Cell Therapy Center Benefit From Robertson Foundation Donation
• Cystodistension: No Standards And No Benefits-Survey Of UK Practice - When Data Is Limited, The Place Of Hydrodistention And Hunner’s Lesion Ablation
• $1.2 Million Award from NIST Facilitates Groundbreaking Study Of Wireless Body Area Networks
• Early Identification Of Alzheimer’s Disease With PET Scan
• ACC: ACCORD Vindicates Patient-Centered Cardiac Care in Diabetes
• ACC: FDA Announces Review of ACCORD Data
• User Involvement In Local Diabetes Care - Get Involved, UK
• Research Findings Aim To Improve The Lives Of Rheumatoid Arthritis Patients
• Bone Plays Key Role In Insulin Regulation
• Fertility Clinics Seek To Improve Access By Lowering Costs, Increasing Providers